Cargando…
Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World
CONTEXT: Advent of trastuzumab has brought tremendous changes in the survival of human epidermal growth factor receptor 2 (Her2)-positive breast cancer patients. Despite the availability of the drug, it is still out of reach for many patients. There is very limited real world data regarding treatmen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398102/ https://www.ncbi.nlm.nih.gov/pubmed/28469333 http://dx.doi.org/10.4103/0971-5851.203511 |
_version_ | 1783230403198320640 |
---|---|
author | Adusumilli, Praveen Konatam, Meher Lakshmi Gundeti, Sadashivudu Bala, Stalin Maddali, Lakshmi Srinivas |
author_facet | Adusumilli, Praveen Konatam, Meher Lakshmi Gundeti, Sadashivudu Bala, Stalin Maddali, Lakshmi Srinivas |
author_sort | Adusumilli, Praveen |
collection | PubMed |
description | CONTEXT: Advent of trastuzumab has brought tremendous changes in the survival of human epidermal growth factor receptor 2 (Her2)-positive breast cancer patients. Despite the availability of the drug, it is still out of reach for many patients. There is very limited real world data regarding treatment challenges and survival analysis of these patients. AIMS AND OBJECTIVES: Primary objective is disease-free survival (DFS) and secondary objective is overall survival (OS) and toxicity profile. STATISTICS: Statistical analysis is done using GraphPad Prism 7.02. MATERIALS AND METHODS: This is a retrospective study of all patients diagnosed with Her2-positive (Her2+) nonmetastatic invasive breast cancer from January 2007 to December 2013. RESULTS: In the period of this study, 885 patients are diagnosed with carcinoma breast, of which 212 are Her2/neu positive (23.9%). Of the 212 patients, only 76 (35.8%) patients received trastuzumab along with chemotherapy. Patients receiving trastuzumab with chemotherapy have longer 5-year DFS compared to those receiving chemotherapy alone, 92% and 52.6%, respectively (P = 0.0001). Five-year OS is 90.5% and 41.7% in those patients who received chemotherapy with and without trastuzumab, respectively (P = 0.0001). Seven patients (9.45%) developed Grade II reversible diastolic dysfunction. Grade II/III peripheral neuropathy due to paclitaxel is the main adverse effect seen in 21 patients. CONCLUSION: In spite of improvement in DFS and OS with trastuzumab, the number of patient receiving targeted therapy is very low due to financial constraints which need to be addressed to bridge the gap in survival of Her2+ patients. |
format | Online Article Text |
id | pubmed-5398102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-53981022017-05-03 Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World Adusumilli, Praveen Konatam, Meher Lakshmi Gundeti, Sadashivudu Bala, Stalin Maddali, Lakshmi Srinivas Indian J Med Paediatr Oncol Original Article CONTEXT: Advent of trastuzumab has brought tremendous changes in the survival of human epidermal growth factor receptor 2 (Her2)-positive breast cancer patients. Despite the availability of the drug, it is still out of reach for many patients. There is very limited real world data regarding treatment challenges and survival analysis of these patients. AIMS AND OBJECTIVES: Primary objective is disease-free survival (DFS) and secondary objective is overall survival (OS) and toxicity profile. STATISTICS: Statistical analysis is done using GraphPad Prism 7.02. MATERIALS AND METHODS: This is a retrospective study of all patients diagnosed with Her2-positive (Her2+) nonmetastatic invasive breast cancer from January 2007 to December 2013. RESULTS: In the period of this study, 885 patients are diagnosed with carcinoma breast, of which 212 are Her2/neu positive (23.9%). Of the 212 patients, only 76 (35.8%) patients received trastuzumab along with chemotherapy. Patients receiving trastuzumab with chemotherapy have longer 5-year DFS compared to those receiving chemotherapy alone, 92% and 52.6%, respectively (P = 0.0001). Five-year OS is 90.5% and 41.7% in those patients who received chemotherapy with and without trastuzumab, respectively (P = 0.0001). Seven patients (9.45%) developed Grade II reversible diastolic dysfunction. Grade II/III peripheral neuropathy due to paclitaxel is the main adverse effect seen in 21 patients. CONCLUSION: In spite of improvement in DFS and OS with trastuzumab, the number of patient receiving targeted therapy is very low due to financial constraints which need to be addressed to bridge the gap in survival of Her2+ patients. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5398102/ /pubmed/28469333 http://dx.doi.org/10.4103/0971-5851.203511 Text en Copyright: © 2017 Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Adusumilli, Praveen Konatam, Meher Lakshmi Gundeti, Sadashivudu Bala, Stalin Maddali, Lakshmi Srinivas Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title | Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title_full | Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title_fullStr | Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title_full_unstemmed | Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title_short | Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World |
title_sort | treatment challenges and survival analysis of human epidermal growth factor receptor 2-positive breast cancer in real world |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398102/ https://www.ncbi.nlm.nih.gov/pubmed/28469333 http://dx.doi.org/10.4103/0971-5851.203511 |
work_keys_str_mv | AT adusumillipraveen treatmentchallengesandsurvivalanalysisofhumanepidermalgrowthfactorreceptor2positivebreastcancerinrealworld AT konatammeherlakshmi treatmentchallengesandsurvivalanalysisofhumanepidermalgrowthfactorreceptor2positivebreastcancerinrealworld AT gundetisadashivudu treatmentchallengesandsurvivalanalysisofhumanepidermalgrowthfactorreceptor2positivebreastcancerinrealworld AT balastalin treatmentchallengesandsurvivalanalysisofhumanepidermalgrowthfactorreceptor2positivebreastcancerinrealworld AT maddalilakshmisrinivas treatmentchallengesandsurvivalanalysisofhumanepidermalgrowthfactorreceptor2positivebreastcancerinrealworld |